We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Byetta Indication Expanded, Labeling Gets New Warning
Byetta Indication Expanded, Labeling Gets New Warning
November 6, 2009
Amylin Pharmaceuticals and Eli Lilly’s injectable Type 2 diabetes drug Byetta has received FDA approval for use as a standalone treatment, but the label also has been updated with warnings about pancreatitis and possible kidney function impairment.